Reply to E.A. Rakha et al
J Clin Oncol
.
2015 Apr 10;33(11):1302-4.
doi: 10.1200/JCO.2014.59.7559.
Epub 2015 Mar 9.
Authors
Antonio C Wolff
1
,
M Elizabeth H Hammond
2
,
David G Hicks
3
,
Kimberly H Allison
4
,
John M S Bartlett
5
,
Michael Bilous
6
,
Patrick Fitzgibbons
7
,
Wedad Hanna
8
,
Robert B Jenkins
9
,
Pamela B Mangu
10
,
Soonmyung Paik
11
,
Edith A Perez
12
,
Michael F Press
13
,
Patricia A Spears
14
,
Gail H Vance
15
,
Giuseppe Viale
16
,
Mitch Dowsett
17
,
Lisa M McShane
18
,
Daniel F Hayes
19
Affiliations
1
Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD.
2
University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT.
3
University of Rochester Medical Center, Rochester, NY.
4
Stanford University Medical Center, Stanford, CA.
5
Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
6
University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia.
7
St Jude Medical Center, Fullerton, CA.
8
Sunnybrook Health Sciences Center, Toronto, Ontario, Canada.
9
Mayo Clinic, Rochester, MN.
10
American Society of Clinical Oncology, Alexandria, VA.
11
National Adjuvant Surgical Breast and Bowel Project, Pittsburgh, PA.
12
Mayo Clinic, Jacksonville, FL.
13
University of Southern California, Los Angeles, CA.
14
North Carolina State University, Raleigh, NC.
15
Indiana University Medical Center, Indianapolis, IN.
16
University of Milan, European Institute of Oncology, Milan, Italy.
17
Royal Marsden Hospital, London, United Kingdom.
18
National Cancer Institute, Bethesda, MD.
19
University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.
PMID:
25753441
DOI:
10.1200/JCO.2014.59.7559
No abstract available
Publication types
Comment
MeSH terms
Biomarkers, Tumor / genetics*
Breast Neoplasms / genetics*
Female
Humans
Medical Oncology / standards*
Receptor, ErbB-2 / genetics*
Substances
Biomarkers, Tumor
Receptor, ErbB-2
Grants and funding
P30 CA006973/CA/NCI NIH HHS/United States